Extensive evidence indicates that serum response factor (SRF) regulates muscle-specific gene expression and that the myocardin family SRF co-factors are critical for smooth muscle cell 
Introduction
The MADS (MCM1, Agamous, Deficiens, SRF) box transcription factor, serum response factor (SRF), regulates cell-type-specific gene expression in cardiac, skeletal, and smooth muscle by binding to CArG elements present in most of the muscle differentiation marker gene promoters. Although SRF is highly expressed in all three muscle cell-types, it is a ubiquitously expressed factor that also regulates several early response growth genes including c-fos and egr-1 (1, 5, 30, 34, 35) . Extensive evidence indicates that SRF activity is regulated mainly by its physical interaction with additional general and cell-type-specific transcription factors. The first SRF co-factors identified were the ternary complex factors (Elk-1, Sap-1, SAP-2/NET/ERP) that bind to SRF as well as to the Ets domain adjacent to the c-fos CArG following their phosphorylation by MAP kinase (see (2) for review). SRF has also been shown to interact with cell-type specific factors such as MyoD and GATA-4 to regulate skeletal and cardiac musclespecific gene expression, respectively (26, 29) .
The discovery of myocardin was a major advance in our understanding of the mechanisms that regulate SMC differentiation. This SRF co-factor is specifically expressed in cardiac and smooth muscle, powerfully stimulates SRF-dependent transcription in a variety of cell-types, and is critical for SMC differentiation in vivo (6, 20, 36) . Two Myocardin-Related Transcription Factors, MRTF-A and MRTF-B were also described that have similar activities to that of myocardin (37) . Although the MRTFs are expressed more widely, recent results in knockout mice indicate that MRTF-B is required for SMC differentiation of cardiac neural crest cells while MRTF-A is required for SMC differentiation marker gene expression that normally occurs in the myoepithelial layer of the mammary gland during lactation (18, 19, 25, 31) . Interestingly, the myocardin factors are differentially regulated by sub-cellular localization, and our lab and others have shown that RhoA-dependent nuclear translocalization of the MRTFs is an important mechanism by which some extrinsic factors stimulate SMC-specific gene expression (9, 13, 21, 22) .
To identify additional factors involved in the regulation of SRF-dependent SMC-specific transcription, we conducted a yeast-two-hybrid screen of a human aortic library using an amino terminal version of SRF (aa 1-201) as bait. Three of the clones identified coded for Four and a
Half LIM domain-containing protein 2 (FHL2), a LIM-only protein that has been shown to be selectively expressed in the heart and SMC during development (8) (16) (33) and that functions as a transcriptional co-activator or co-repressor for a variety of transcription factors including the androgen receptor, cAMP-responsive element binding protein, AP-1, FOXO1, E4F1, andcatenin (see (16) for review). Since FHL2 does not bind DNA directly, these effects are thought to be mediated by FHL2's ability to facilitate protein-protein interactions through its multiple LIM domains.
In addition to its expression pattern during development, several features of FHL2 function led us to examine its role in regulating SMC-and cardiac-specific transcription. First, Müller et al demonstrated that, like the MRTFs, FHL2 nuclear localization and transactivation were dependent upon RhoA signaling (24) . Second, Philippar et al used a genetic screen in SRF -/-ES cells to identify FHL2 as an SRF target gene whose up-regulation correlated with increased SMC-specific gene expression in an ES cell model of SMC differentiation (27) . These authors demonstrated that FHL2 interacted physically with SRF and that over-expression of FHL2 inhibited RhoA-dependent activation of SM22. Finally, Chang et al demonstrated that the SMCspecific LIM only proteins, CRP1 and CRP2, stimulated SMC-specific transcription by facilitating SRF's interaction with GATA factors (3, 4) .
Our results confirm that FHL2 interacts with SRF, but we also demonstrate that FHL2 binds directly to all three myocardin factors and has differential effects on their abilities to regulate cardiac and SMC-specific transcription. Importantly, FHL2 increased myocardin and MRTF-A transactivation and this effect may be due to protection of these factors from proteasomal degradation.
Materials and Methods
Yeast 2-hybrid screen and plasmid construction -FHL2 was identified in a Matchmaker yeast two hybrid screen (Clontech) using the SRF N-terminus (aa 1-201) as bait. Full length FHL2 was subcloned into flag-pcDNA3 and PGEX4T1 vectors. Expression constructs for SRF, L63RhoA, Myocardin, MRTF-A, MRTF-B, and myocardin factor derivatives have been previously described (13, 21) . The GST fusions, FHL2 0-2 and FHL2 3/4, were generous gifts from Roland Schüle (University of Freiburg, Freiburg, Germany) and have been previously described (23) .
Cell Culture, Transient Transfections, and Reporter Assays -The rat aortic SMC and 10T1/2 cultures and the SMC-specific promoter assays used have been previously described (21) . In brief, cells were maintained in 10% serum media and transfected 24 h after plating at 70-80% confluency using LT-1 transfection reagent (Mirus) per protocol. Luciferase activity measurements were made 24 h post transfection. Luciferase activity was measured in relative light units (RLUs) and expressed as fold activity over empty vector. For harvesting of protein, cells were plated in 15cm dishes and lysed in RIPA + 0.5% triton.
GST fusion pull-downs and co-immunoprecipitations -GST pull-down assays and coimmunoprecipitations were performed as previously described (32) . In brief, GST fusion proteins were purified from bacterial lysates using glutathione sepharose (Amersham Biosciences). Interacting proteins were in vitro translated and 35S labeled using the Promega TnT kit. Interacting complexes were pelleted by centrifugation and washed 2X in NETN solution and 1X in cold Tris-buffered saline. For co-immunoprecipitations flag-FHL2 was expressed in 10T1/2 cells and immunoprecipitations were performed using anti-flag or anti-SRF Abs.
Semi-quantitative PCR -RNA was prepared from cell and tissue lysates using Trizol Reagent (Invitrogen) and was quantified by Ribogreen Assay (Molecular Probes). cDNA was generated from 1ug of RNA using in the iScript cDNA synthesis kit (Biorad). Exon spanning primers were used to amplify FHL2, myocardin, MRTF-A, MRTF-B and GAPDH (sequences available upon request).
Electrophoretic Mobility Shift Assays -FHL2, SRF and myocardin factors were in vitro translated using the Promega TnT kit. Binding reactions contained 5ul of total TnT lysate, a 32P-labeled SM a-actin Intronic CArG probe (20,000 cpm), and 0.25 µg dI·dC in binding buffer (10 mM Tris, pH 7.5, 50 mM NaCl, 100 mM KCl, 1 mM dithiothreitol, 1 mM EDTA, 5% glycerol).
Reactions were incubated for 30 m before loading on a nondenaturing 5% polyacrylamide gel. Blots were performed on immunoprecipitants using the P4G7 anti-ubiquitin antibody (Covance). These data confirm the observation by Philippar et al that FHL2 interacts with SRF (27) . FHL2 was originally thought to be specifically expressed in the myocardium, but examination of mice containing LacZ knocked into the endogenous FHL2 locus revealed high expression of FHL2 in the developing vasculature (8) . To specifically examine FHL2 expression in adult smooth muscle, we used semi-quantitative RT-PCR (Fig 1d) . As expected, FHL2 message was highest in the heart, but significant levels were also detected in tissues that contain a large SMC component including aorta, bladder, esophagus, and stomach. In addition, FHL2 expression was very high in primary rat aortic and A7r5 SMC, weak in multipotential 10T1/2 cells, and absent in cos-7 cells. FHL1, which has also been shown to be expressed in the developing heart and outflow tract, was expressed in a similar pattern (data not shown). (Fig 2b) . In addition, endogenous MRTF-A co-immunoprecipitated with flag-FHL2 expressed in 10T1/2 cells, further suggesting that these proteins interact in vivo (Fig 2c) .
Sub-cellular Localization Studies

Determination of MRTF-A half-life -
We also mapped the domains of the myocardin factors that interacted with FHL2. As shown in figure 2d-f, FHL2 bound most strongly to myocardin, MRTF-A, and MRTF-B through an N-terminal fragment that contained the RPEL motifs, the two basic domains, and the Q-rich region. Interestingly, FHL2 bound fairly strongly to a myocardin fragment that contained only the RPEL motifs and basic domain 2 (Fig 2d) and to an MRTF-B fragment that contained only basic domain 1, the Q-rich region, and the SAP domain (Fig 2f) . Taken together, these results suggest that the region near basic domain 1 is probably the most important for FHL2 binding.
The slight differences in FHL2 binding to the myocardin factors were somewhat surprising and suggested that FHL2 may have differential effects on the myocardin factors.
FHL2 enhanced myocardin and MRTF-A transactivation. To test whether FHL2 had
functional effects on myocardin factor activity we co-expressed FHL2 with each of the myocardin factors along with the SM -actin and SM22 promoters in multipotential 10T1/2 cells.
In these experiments we transfected sub-maximal levels of myocardin, MRTF-A, and MRTF-B that activated these promoters by approximately 60, 45 and 10 fold, respectively (data not shown). As shown in figure 3 , co-expression of FHL2 dose-dependently increased myocardin's ability to stimulate SMC-specific promoter activity. In stark contrast, FHL2 inhibited transactivation by MRTF-B, and slightly stimulated transactivation by MRTF-A but only at high concentrations. Because FHL2 expression is the highest in the myocardium, we also examined the effects of FHL2 on the cardiac-specific atrial natriuretic factor (ANF) promoter. Similar to effects observed with the SMC-specific promoters, FHL2 increased transactivation of ANF by myocardin and MRTF-A. We initially hypothesized that FHL2 increased myocardin and MRTF-A activity by facilitating their interactions with SRF. However, expression of FHL2 had no effect on the association of SRF and MRTF-A as measured by co-immunoprecipitation of proteins from 10T1/2 lysates (Fig 2c) and did not increase ternary complex formation between SRF and the myocardin factors in gel shift assays (see Fig 6, below) .
To further explore the role of FHL2 in SMC differentiation marker gene expression, we used siRNA to knock down FHL2 expression in primary rat aortic SMC. As shown in figure 3d, knockdown of FHL2 expression by 90% led to an approximately 50% decrease in the activities of the SM -actin, SM22, and calponin promoters.
FHL2 protected myocardin and MRTF-A from proteasome-mediated degradation.
A recent report demonstrated that FHL2 is a target for the ubiquitin E3 ligase, Murf3 (10). Given that other LIM domain containing proteins can inhibit proteasome-mediated degradation by interacting with E3 ligases or ubiquitin targets (15, 28), we tested whether myocardin factor protein levels were regulated by proteasomal degradation and whether the positive effects of FHL2 on myocardin factor activity were due to inhibition of this pathway. We have recently generated a highly specific monoclonal antibody for MRTF-A that we first used to determine whether endogenous MRTF-A protein levels were affected by FHL2 expression. Even with a transfection efficiency of only 40-50% (measured by parallel transfection of GFP), overexpression of FHL2 in 10T1/2 cells led to a significant increase (~3-fold) in MRTF-A protein as measured by Western Blot (Fig 4a) . Importantly, over-expression of FHL2 did not affect myocardin factor mRNA levels (Fig 4b) . Treatment of cells with the proteasome inhibitor MG132 resulted in a slightly larger increase in endogenous MRTF-A protein in both 10T1/2 cells and primary rat aortic SMC (Fig 4c) .
We were also interested in the effects of FHL2 on myocardin and MRTF-B protein levels, but because we have had little success in measuring myocardin or MRTF-B protein levels with the available antibodies, we co-transfected FHL2 along with flag-tagged versions of all three myocardin factors into 10T1/2 cells. As shown in figure 4d, over-expression of FHL2 led to increased levels of exogenously expressed myocardin (compare lanes 1 and 2) and MRTF-A (lanes 3 and 4), but had no effect on levels of MRTF-B (lanes 5 and 6). MG132 treatment led to more dramatic increase in myocardin and MRTF-A protein, and slightly increased MRTF-B levels (Fig. 4e, compare lanes 1 and 2) . Interestingly, FHL2 expression had little if any effect on myocardin and MRTF-A levels in MG132-treated cells (compare lanes 2 and 4). We observed very similar changes in myocardin factor protein levels upon treatment of cells with lactacystin, a more specific inhibitor of the proteasome (Fig. 4f) .
Interestingly, FHL2's ability to protect the myocardin factors from degradation correlated fairly well with myocardin factor nuclear localization. For example, myocardin, which is constitutively nuclear, was protected from degradation by FHL2. In contrast, MRTF-B, which is frequently cytoplasmic, was not up-regulated by FHL2 expression. To test this more rigorously, we compared the effects of MG132 and FHL2 on N MRTF-B which lacks the N-terminal RPEL motifs that are required for localization of MRTF-B to the cytoplasm. N MRTF-B levels were much lower than full-length MRTF-B levels under control conditions, and unlike fulllength MRTF-B, N MRTF-B protein levels were up-regulated by FHL2 co-expression and were strongly up-regulated by MG132 treatment (Fig 4e; bottom panel) .
To directly measure the effects of FHL2 on MRTF-A protein stability we treated cells with the protein synthesis inhibitor, cycloheximide and measured MRTF-A protein by Western blot at 0.5, 3, and 6 h. As shown in figure 5 , the half-life of over-expressed or endogenous MRTF-A was approximately 3 h and was significantly extended by the expression of FHL2 (Figs 5a and 5b) or by proteasome inhibition (Fig 5c) . Note that the protein half-life of FHL2 was substantially shorter (~1.5 h).
To determine whether the myocardin factors were targeted to the proteasome by ubiquitylation, we immunoprecipitated MRTF-A from MG132-treated and control SMC and probed immunoprecipitates with an anti-ubiquitin antibody. As shown in figure 5d, ubiquitin immunoreactivity was only detected in MRTF-A (not control IgG) immunoprecipitants, and treatment of SMC with MG132 resulted in a substantial increase in this signal.
FHL2 did not increase myocardin factor association with SRF and may negatively regulate
SRF-CArG binding. Philippar et al reported that FHL2 expression inhibited RhoA-dependent increases in SM22 and SM -actin promoter activity in 293T cells and based upon gel shift analyses suggested that this effect was due to competitive inhibition of myocardin factor binding to SRF (20) . We observed similar effects of FHL2 on RhoA-dependent stimulation of SMCspecific transcription in our 10T1/2 model (data not shown) and also demonstrated that FHL2 had negative effects on MRTF-B transactivation (Fig 3) . However, our demonstration that FHL2 interacts directly with the myocardin factors and has differential effects on myocardin factor transactivation potentially complicates this model. 
FHL2 modestly inhibited MRTF nuclear translocation. FHL2, like the MRTFs, has been
shown to translocate from the cytoplasm to the nucleus in response to external stimuli that activate RhoA (24) . Given that the effects of RhoA are strongly dependent upon nuclear translocation of the MRTFs, we hypothesized that the inhibitory effects of FHL2 could also be due to inhibition of MRTF-B nuclear translocation. To test this, we co-expressed flag-FHL2 along with EGFP-MRTF-B fusion proteins. MRTF-B localization under serum-free conditions was scored as nuclear, cytoplasmic, or diffuse (nuclear + cytoplasmic). As shown in figure 6b, expression of FHL2 slightly increased the percentage of cells exhibiting strictly cytoplasmic localization and decreased the percentage of cells exhibiting diffuse localization.
Discussion
FHL2 has been shown to interact with a large number of transcription factors in a number of different model systems and has been shown to have both positive and negative effects on gene expression (see (16) for review). The goal of the present study was to further characterize the effects of FHL2 on SRF-dependent transcription. While our results confirm a previous report that FHL2 interacts directly with SRF, they also suggest that FHL2's role in the regulation of SRF-dependent transcription is complicated by additional interactions with the myocardin family of SRF co-factors. We demonstrate for the first time that expression of FHL2 stimulates myocardin-dependent transactivation of cardiac and SMC-specific promoter activity and that these effects are most likely due to protection of myocardin and MRTF-A from proteasomal degradation. Thus, based upon the known expression pattern of FHL2 during development, we propose that FHL2 promotes cardiac and SMC differentiation by preserving myocardin factor protein levels. In addition, since the FHL2 and SRF promoters are both regulated by SRF (27) (and probably the myocardin factors), FHL2 could be a key component of a feed-forward mechanism that maintains high levels of cardiac-and/or SMC-specific gene expression.
These studies demonstrate that the myocardin factors are tightly regulated by the proteasome and may provide a novel mechanism for the control of cardiac and SMC-specific transcription. During the final revision of this manuscript, Elberg et al reported that addition of proteasome inhibitor MG132 or Z-LLF also prevented degradation of MRTF-A in renal tubular epithelial cells. This study provides excellent support for the data presented here, and suggests that the myocardin factors are regulated by the proteasome in multiple cell types (10). Our finding that endogenous MRTF-A is ubiquitylated suggests that the myocardin factors may be direct targets for the proteasome, but it remains possible that myocardin factor stability is also regulated by another mechanism that is proteasome-sensitive. In addition, although the effects of (38) . These authors observed that FHL2 was activated in skin myofibroblasts following wounding and that FHL2 expression correlated with the activation of SM -actin and SM22 expression that is known to occur in this model (14) . Furthermore, they demonstrated that FHL2 -/-mice exhibited reduced SM -actin expression and healing following wounding and that re-expression of FHL2 in FHL2 -/-MEFs and mesenchymal stem cells up-regulated SM -actin promoter activity. These results support a closer examination of the role of FHL2 in the modulation of SMC phenotype following vessel injury.
In summary, FHL2 has multiple effects on SRF-and myocardin factor-dependent transcription. Our data suggest that that FHL2 protects myocardin and MRTF-A from proteasome mediated degradation, providing a novel mechanism for the control of myocardin factor activity. It will be very important to further characterize this regulatory mechanism in cardiac and SMC and to test whether FHL2 (and perhaps other FHL family members) has similar effects on other transcription factors. 
